Predicting Survival in Colorectal Liver Metastasis: Time for New Approaches Georgios Antonios MargonisNikolaos AndreatosMurray F. Brennan Hepatobiliary Tumors 31 August 2020 Pages: 4861 - 4863
The Interplay of Primary Tumor Location and KRAS Mutation Status in Patients with Synchronous Colorectal Cancer Liver Metastases: Current Data and Unanswered Questions Georgios Antonios MargonisNikolaos AndreatosMichael D’Angelica Hepatobiliary Tumors 21 September 2020 Pages: 4864 - 4866
Patterns of Failure and Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation Rebecca M. ShulmanJoshua E. Meyer Hepatobiliary Tumors 17 August 2020 Pages: 4867 - 4869
Melanomas of Unknown Primary May Have a Distinct Molecular Classification to Explain Differences in Patient Outcomes Georgia M. Beasley Melanoma 10 September 2020 Pages: 4870 - 4871
Editorial on “Simultaneous Ipsilateral Vascularized Lymph Node Transplantation and Contralateral Lymphovenous Anastomosis in Bilateral Different-Severities Extremity Lymphedema” Mark V. Schaverien Reconstructive Oncology 25 June 2020 Pages: 4872 - 4873
Dextrose-Containing Carrier Solution for Hyperthermic Intraperitoneal Chemotherapy: Increased Intraoperative Hyperglycemia and Postoperative Complications Robert J. TorphyCamille StewartSteven A. Ahrendt Peritoneal Surface Malignancy 19 April 2020 Pages: 4874 - 4882
Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study Benjamin D. PowersSeth FelderSean P. Dineen Peritoneal Surface Malignancy 21 April 2020 Pages: 4883 - 4891
ASO Author Reflections: To Redo or Not to Redo, That is the Question: Assessing the Slings and Arrows of Repeat CRS/HIPEC in Patients with Recurrent or Progressive Peritoneal Carcinomatosis Benjamin D. PowersSean P. Dineen ASO Author Reflections 21 April 2020 Pages: 4892 - 4893
The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC Michael K. TurgeonAdriana C. GamboaJoshua H. Winer Peritoneal Surface Malignancy 06 May 2020 Pages: 4894 - 4907
Impact of Mucin Cellularity and Distribution on Survival in Newly Diagnosed Patients with Low-Grade Appendiceal Mucinous Neoplasm Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Andrei NikiforchinMary Caitlin KingArmando Sardi Peritoneal Surface Malignancy 14 May 2020 Pages: 4908 - 4917
ASO Author Reflections: Not All Low-Grade Appendiceal Mucinous Neoplasm Mucin is Created Equal Andrei NikiforchinVadim GushchinArmando Sardi ASO Author Reflections 20 May 2020 Pages: 4918 - 4919
What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor? Patrick B. SchwartzChristopher C. StahlDaniel E. Abbott Peritoneal Surface Malignancy 15 May 2020 Pages: 4920 - 4928
ASO Author Reflections: Predictors of Fiscal Outcomes in CRS-HIPEC and Opportunities for Improvement Patrick B. SchwartzDaniel E. Abbott ASO Author Reflections 16 May 2020 Pages: 4929 - 4930
Pelvic Anastomosis Without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Ekaterina BaronVadim GushchinArmando Sardi Peritoneal Surface Malignancy 06 June 2020 Pages: 4931 - 4940
ASO Author Reflections: Is CRS/HIPEC an Indication to Divert Rectal Anastomosis? Ekaterina BaronVadim GushchinArmando Sardi ASO Author Reflections 27 May 2020 Pages: 4941 - 4942
Rate of Peritoneal Carcinomatosis in Resected Stage II and III Colon Cancer Audrey H. ChoiCyrus FarzanehMaheswari Senthil Peritoneal Surface Malignancy 14 June 2020 Pages: 4943 - 4948
ASO Author Reflections: Real-World Incidence of Peritoneal Carcinomatosis After Colon Cancer Resection and Why It Matters Audrey H. ChoiMaheswari Senthil ASO Author Reflections 06 July 2020 Pages: 4949 - 4949
Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform Steven D. ForsytheShyama SasikumarKonstantinos I. Votanopoulos Peritoneal Surface Malignancy 06 July 2020 Pages: 4950 - 4960
ASO Author Reflections: Patient-Derived Tumor Organoids—A Platform for a Precision Approach for Peritoneal Malignancies Steven D. ForsytheOmeed MoavenKonstantinos I. Votanopoulos ASO Author Reflections 27 July 2020 Pages: 4961 - 4962
Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis Michael G. WhiteAnai KothariBrian Badgwell Peritoneal Surface Malignancy 09 July 2020 Pages: 4963 - 4969
Robotic Major Hepatectomy: An Institutional Experience and Clinical Outcomes Iswanto SucandyKenneth LubericeAlexander Rosemurgy Peritoneal Surface Malignancy 13 July 2020 Pages: 4970 - 4979
Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative Adriana C. GamboaRachel M. LeeCharles A. Staley Peritoneal Surface Malignancy 21 July 2020 Pages: 4980 - 4995
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative David RoifeBenjamin D. PowersSean P. Dineen Peritoneal Surface Malignancy 18 October 2020 Pages: 4996 - 5004
Cellular Immunoprofile of Peritoneal Environment During a HIPEC Procedure Jan FrankoRushin BrahmbhattMatthew Andres Peritoneal Surface Malignancy 21 July 2020 Pages: 5005 - 5013
ASO Author Reflections: Characterizing the Peritoneal Immune Response to the Surgical and Thermal Trauma of Peritoneal Cytoreduction and HIPEC Jan FrankoBenjamin FerrelMarc Gorvet ASO Author Reflections 27 July 2020 Pages: 5014 - 5015
Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC Omeed MoavenJing SuLance D. Miller Peritoneal Surface Malignancy 23 July 2020 Pages: 5016 - 5023
ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies Omeed MoavenLance D. MillerEdward A. Levine ASO Author Reflections 04 August 2020 Pages: 5024 - 5025
Defining “Complete Cytoreduction” After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis Carlos A. Munoz-ZuluagaMary C. KingArmando Sardi Peritoneal Surface Malignancy 23 July 2020 Pages: 5026 - 5036
ASO Author Reflections: Time to Change: Redefining “Complete Cytoreduction” in Appendiceal Carcinomatosis Carlos Munoz-ZuluagaMary Caitlin KingArmando Sardi ASO Author Reflections 15 September 2020 Pages: 5037 - 5038
Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement Jason B. LiuDarryl SchuitevoerderOliver S. Eng Peritoneal Surface Malignancy 29 July 2020 Pages: 5039 - 5046
Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma Alisa N. BlumenthalerCasey J. AllenBrian D. Badgwell Peritoneal Surface Malignancy 31 July 2020 Pages: 5047 - 5056
Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer Hideyuki OhzawaYuki KimuraJoji Kitayama Peritoneal Surface Malignancy 17 August 2020 Pages: 5057 - 5064
Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies Katie M. LeickAustin G. KazarianCarlos H. F. Chan Translational Research 09 July 2020 Pages: 5065 - 5071
ASO Author Reflections: Potential Values of Peritoneal Cell-Free Tumor DNA Testing Carlos H. F. Chan ASO Author Reflections 19 October 2020 Pages: 5072 - 5073
Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases Scott K. ShermanDarryl SchuitevoerderKiran K. Turaga Colorectal Cancer 24 June 2020 Pages: 5074 - 5083
ASO Author Reflections: Mismatch Repair and Survival in Metastatic Colorectal Cancer Scott K. ShermanCarlos H. F. Chan ASO Author Reflections 06 July 2020 Pages: 5084 - 5085
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases John M. CreasyKyle J. NapierMichael E. Lidsky Colorectal Cancer 10 August 2020 Pages: 5086 - 5095
ASO Author Reflections: Implementation of a New Hepatic Artery Infusion Program for Colorectal Liver Metastases is Safe, Feasible, and Effective John M. CreasyMichael E. Lidsky ASO Author Reflections 19 August 2020 Pages: 5096 - 5097
Short-Term Risk of Performing Concurrent Procedures with Hepatic Artery Infusion Pump Placement Brian C. BrajcichDavid J. BentremRyan P. Merkow Hepatobiliary Tumors 01 August 2020 Pages: 5098 - 5106
Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia Michael J. CarrJames SunJonathan S. Zager Melanoma 11 September 2020 Pages: 5107 - 5118
ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma Michael J. CarrHidde M. KroonJonathan S. Zager ASO Author Reflections 11 September 2020 Pages: 5119 - 5120
Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy Norma E. FarrowVignesh RamanGeorgia M. Beasley Melanoma 20 April 2020 Pages: 5121 - 5125
ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy Norma E. FarrowGeorgia M. Beasley ASO Author Reflections 14 May 2020 Pages: 5126 - 5127
Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management Daan Jan Willem RauwerdinkGeorge MolinaGenevieve Marie Boland Melanoma 23 May 2020 Pages: 5128 - 5136
ASO Author Reflections: Adjuvant Treatment of Melanoma in the Modern Era Daan Jan Willem RauwerdinkGenevieve Marie Boland ASO Author Reflections 28 May 2020 Pages: 5137 - 5138
A Novel Machine-Learning Approach to Predict Recurrence After Resection of Colorectal Liver Metastases Anghela Z. ParedesJ. Madison HyerTimothy M. Pawlik Hepatobiliary Tumors 10 August 2020 Pages: 5139 - 5147
ASO Author Reflections: Development and Validation of a Novel Risk Score Using Machine-Learning Methodology to Predict Recurrence After Hepatectomy for Colorectal Liver Metastases Anghela Z. ParedesDiamantis I. TsilimigrasTimothy M. Pawlik ASO Author Reflections 09 August 2020 Pages: 5148 - 5149
Prognosis of Synchronous Colorectal Liver Metastases After Simultaneous Curative-Intent Surgery According to Primary Tumor Location and KRAS Mutational Status Ho Seung KimJong Min LeeNam Kyu Kim Hepatobiliary Tumors 18 August 2020 Pages: 5150 - 5158
ASO Author Reflections: Poorest Survival Outcomes in Patients with Right Colon Cancer with KRAS Mutation After Simultaneous Curative-Intent Surgery for Colorectal Cancer Liver Metastases Ho Seung KimNam Kyu Kim ASO Author Reflections 19 August 2020 Pages: 5159 - 5160
Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation Edward Christopher DeeMorgan E. FreretJennifer Y. Wo Hepatobiliary Tumors 01 August 2020 Pages: 5161 - 5172
